PierFranco Conte

Research interests

Publications

• Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.11.011

• Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

  New England Journal of Medicine · 2020 · 10.1056/nejmoa2004407

• Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.05.001

• OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz012

• Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1813904

• The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

  JAMA Oncology · 2019 · https://doi.org/10.1001/jamaoncol.2019.4782

• HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

  JNCI Journal of the National Cancer Institute · 2019 · https://doi.org/10.1093/jnci/djz042

• Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy155

• nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy201

• Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2016.67.4887

• Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30450-3

• Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1706450

• Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1609709

• PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

  Annals of Oncology · 2016 · https://doi.org/10.1093/annonc/mdw197

• Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials

  Annals of Oncology · 2015 · 10.1093/annonc/mdv239

• Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel

  Annals of Oncology · 2015 · https://doi.org/10.1093/annonc/mdv617

• Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdt556

• Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study

  Journal of Clinical Oncology · 2012 · 10.1200/jco.2011.39.0823

• Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

  Journal of Clinical Oncology · 2012 · 10.1200/jco.2011.37.4207

• Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery for Cancer Therapy

  Cancer Research · 2010 · 10.1158/0008-5472.can-09-1865

• Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.24.2024

• Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer

  Breast Cancer Research and Treatment · 2010 · 10.1007/s10549-010-0866-3

• Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

  Journal of Clinical Oncology · 2007 · 10.1200/jco.2006.08.9102

• Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM

  Cytotherapy · 2006 · 10.1080/14653240600920782

• Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.04.173

• Survival of metastatic breast carcinoma patients over a 20‐year period

  Cancer · 2005 · 10.1002/cncr.21359

• Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

  Journal of Clinical Oncology · 2000 · https://doi.org/10.1200/jco.2000.18.17.3068

• Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

  Journal of Clinical Oncology · 1996 · 10.1200/jco.1996.14.9.2552

• Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.

  Journal of Clinical Oncology · 1996 · https://doi.org/10.1200/jco.1996.14.6.1858

• Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials

  · 1991

Current projects

No projects listed.